All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub was pleased to speak to Guillermo Garcia-Manero, MD Anderson Cancer Centre, Houston, US, about the value of combining structural variant profiling and next-generation sequencing for myelodysplastic syndromes (MDS) prognostication and therapeutic decision-making, based on a recent publication by Garcia-Manero and colleagues in Leukemia.1 We asked, How can structural variant assessment assist in measurable residual disease (MRD) assessment in MDS?
How can structural variant assessment assist in MRD assessment in MDS?
Garcia-Manero begins by discussing the key role of chromosomal banding analysis in the diagnosis and prognosis of patients with MDS, as well its complexities and challenges. Moving forward, Garcia-Manero goes on to consider the advantages of optical genome mapping for structural variant evaluation and the clinical value of this technology, particularly when combined with next-generation sequencing. Garcia-Manero also touches on the future potential of optical genome mapping in acute myeloid leukemia and other hematologic malignancies where chromosomal translocations are relevant.
Real-world validation of the IPSS-M risk stratification model for MDS and comparison to IPSS-R
The MDS Hub summarizes several presentations from ASH 2022 discussing the implementation of IPSS-M and comparing the prognostic ability of this model with...
New IPSS-Molecular model for MDS risk stratification and prognosis
Bernard, et al. evaluated the combined prognostic power of hematologic, cytogenetic, and somatic gene mutation parameters in the development and use of a clinical-molecular...
Subscribe to get the best content related to MDS delivered to your inbox